THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Tuesday, June 29, 2021
Quantitative Systems Pharmacology (QSP), the newest and fastest-growing biosimulation technology, is being hailed as the necessary new strategy for developing neurodegenerative disease medicines.
FREMONT, CA: Millions of people throughout the world suffer from NeurodegenerativeDiseases (NDs). Alzheimer's disease affects five million people in the United States; Parkinson's disease affects one million; multiple sclerosis (MS) affects 400,000 people, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig disease) affects 30,000 people.These conditions vary, but they all involve the progressive degeneration of nerve cells in the brain or nervous system.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Quantitative Systems Pharmacology (QSP), the newest and fastest-growing biosimulation technology, is being hailed as the necessary new strategy for ND drug development. QSP examines the mechanistic links between a drug, the biological system, and the illness process using a combination of computational modeling and experimental approaches. Quantitative drug data is combined with knowledge of the drug's mechanism of action in QSP. As a result, it can help evaluate diseases that are complex and heterogeneous, such as ND.
One of QSP's main advantages is its focus on complete biological systems rather than single pharmacological targets. It enables researchers to take a step back and consider the big picture of the disease's and alternative treatment combinations' influence on the body.
Because NDs patients, particularly those with Alzheimer's disease, are often elderly and have comorbidities, they must take many drugs simultaneously. They will also necessitate individualized care (personalized medicine). Because it allows several quantitative and predictive models to be merged into a single, multiscale simulation platform, QSP modeling is particularly well suited for this application. QSP science, methodology, and technology can be coupled with immunology and inflammatory insights from immuno-oncology research, relevant biomarkers, and data from the genetic, cellular, and neural scales in this scenario.
The NDs simulator that resulted may then be used with a physiologically based Pharmacokinetic (PBPK) simulator to test hypotheses in virtual patient populations with various demographics, ethnicities, and comorbidities. This is particularly relevant because the shift to combination therapy would entail examining more drug combinations than could be tested in clinical trials with real patients practically or ethically.
This paired QSP/PBPK simulator could be used to examine multiple therapeutic modalities, such as small compounds, biologics, antisense oligonucleotides, and gene therapy, in addition to aiding dose selection and optimization for combination therapies. Protein biomarker levels could also be measured in different regions of the body, such as the Cerebrospinal Fluid (CSF) and plasma.
SEE Also: Top Field Service Companies
More in News